Biofrontera Inc. Announces FDA Approval of Biofrontera Pharma GmbH as a Contract Laboratory for Ameluz®
13 avr. 2022 10h10 HE
|
Biofrontera Inc.
Significantly Improves Manufacturing Efficiency, Quality Control and Supply Reliability WOBURN, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical...
Biofrontera Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update
08 avr. 2022 07h42 HE
|
Biofrontera Inc.
Introduces 2022 financial guidanceConference call begins at 11:00 a.m. Eastern time today WOBURN, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a...
Biofrontera Inc. Announces Preliminary Product Revenues for the First Quarter of 2022
06 avr. 2022 08h30 HE
|
Biofrontera Inc.
WOBURN, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today...
Biofrontera Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on April 8, 2022
01 avr. 2022 13h00 HE
|
Biofrontera Inc.
WOBURN, Mass., April 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today it...
Biofrontera to Showcase Actinic Keratoses and Impetigo Treatments at the 2022 American Academy of Dermatology Annual Meeting
17 mars 2022 11h20 HE
|
Biofrontera Inc.
Company to have a strong onsite presence at the world’s largest scientific conference for dermatologists, with approximately 10,000 medical professionals expected to attend WOBURN, Mass., March 17,...
Biofrontera Inc. Announces FDA Orange Book Listing of U.S. Patent for BF-RhodoLED® XL, Extends Protection of Ameluz®-PDT Through October 2040
14 mars 2022 09h25 HE
|
Biofrontera Inc.
WOBURN, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that...
Biofrontera Inc. to Present at the 34th Annual Roth Conference
09 mars 2022 11h08 HE
|
Biofrontera Inc.
WOBURN, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products,...
Biofrontera Inc. Appoints Kevin D. Weber to its Board of Directors
07 mars 2022 08h50 HE
|
Biofrontera Inc.
WOBURN, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products,...
Biofrontera Inc. provides Update on Patient Recruitment for Phase III Study for the Treatment of sBCC with Ameluz®-PDT
01 févr. 2022 08h47 HE
|
Biofrontera Inc.
WOBURN, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, is...
Biofrontera Inc. Issues Letter to Shareholders Highlighting 2021 Successes and Key Elements of the Strategic Plan for 2022 and Beyond
18 janv. 2022 09h25 HE
|
Biofrontera Inc.
WOBURN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today...